Colgate-Palmolive Options Turn Defensive Before Q3 Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Colgate-Palmolive reports its third-quarter results on October 30, and the clearest pre-earnings signal is not in the short book but in the options market, where defensive positioning has reached its most elevated point in months.
The put/call ratio jumped to 0.86 on October 26, more than two standard deviations above its 20-day average of 0.74. That is the sharpest tilt toward downside protection the options market has registered in the run-up to this print, and it arrived on a day when CL fell 1% to close at $93.10, trimming its one-month gain to roughly 8%. Peers moved in the same direction on the day: PG fell 2.8%, CHD dropped 3.4%, and KMB gave back 1.9%, suggesting broader sector pressure rather than a stock-specific catalyst. The lending market tells a different story. Borrow availability is extremely wide at roughly 3,600% of short interest, meaning there are far more shares available to lend than there are positions already borrowed. Cost to borrow is 0.35%, well below anything that suggests a squeeze. Short interest itself has climbed 37% over the past month to reach about 3% of the free float, the highest level in at least a year, but from a low enough base that the short book remains modest by most standards.
The debate around Colgate centres on whether the volume recovery is durable and whether margins can hold against input costs. The bull case rests on international exposure: roughly 70% of sales come from outside the US, with a meaningful share from emerging markets, and the company has backed its positioning with advertising spend running at 13.5% of sales, up from 11.6% in 2021. JP Morgan raised its price target to $104 this month while maintaining an Overweight rating, and RBC Capital and UBS also carry positive ratings above the current $93 price. The bear case is more immediate. Gross margins contracted 75 basis points in Q2 2025 on rising raw material costs and tariffs. Volume was negative in both the first and second quarters of 2025. The Hill's pet food segment, which runs under the brand, showed a 2.8% decline in measured retail channels for Q3 2025. Wells Fargo cut its target to $90 in early October, putting it below where the shares trade. The consensus rating is a hold, with seven analysts at that level and one at underperform, a relatively cautious read for a defensive consumer name.
Insider activity from the 90-day window carries a notable net negative. All recent Form 4 transactions were stock awards or grants, which are compensation events rather than discretionary buying, but the 90-day net figure shows a net disposal of roughly 336,000 shares worth approximately $31 million. That reflects the unwinding of equity compensation rather than fresh conviction. On the institutional register, BlackRock holds about 8.8% and Vanguard entities collectively above 10%, with all major passive holders adding modestly in the most recent periods. Retail attention, measured by Wikipedia page views relative to the prior 90 days, is running at a z-score of 1.6, above average but not extreme.
The October 30 print will test whether the volume trends that turned negative in the first half of 2025 have stabilised, and whether the Hill's segment can arrest its slide, against a margin backdrop where input costs continue to compress the gap between strong pricing and reported profit growth.
Stocks in this article
See the live data behind this article on ORTEX.
Open CL on ORTEX →How this article was generated
- Generated
- 27 Oct 2026, 04:07
- Data as of
- 27 Oct 2026, 04:00
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataIndex Rebalance
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.